{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T18:44:52Z","timestamp":1772304292689,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Multiple endocrine neoplasia type 1 (MEN 1) syndrome is a rare, complex genetic disorder characterized by increased predisposition to tumorigenesis in multiple endocrine and non-endocrine tissues. Diagnosis and management of MEN 1 syndrome is challenging due to its vast heterogeneity in clinical presentation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 23-year-old female, previously diagnosed with Polycystic Ovarian Syndrome (PCOS) and pituitary microprolactinoma presented with drowsiness,confusion and profuse sweating developing over a period of one day. It was preceded by fluctuating, hallucinatory behavior for two weeks duration. There was recent increase in appetite with significant weight gain. There was no fever, seizures or symptoms suggestive of meningism. Her Body mass index(BMI) was 32\u00a0kg\/m<jats:sup>2<\/jats:sup>.She had signs of hyperandrogenism. Multiple cutaneous collagenomas were noted on anterior chest and abdominal wall. Her Glasgow Coma Scale was 9\/15. Pupils were sluggishly reactive to light. Tendon reflexes were exaggerated with up going planter reflexes. Moderate hepatomegaly was present. Rest of the clinical examination was normal. Laboratory evaluation confirmed endogenous hyperinsulinaemic hypoglycaemia suggestive of an insulinoma. Hypercalcemia with elevated parathyroid hormone level suggested a parathyroid adenoma. Presence of insulinoma, primary hyperparathyroidism and pituitary microadenoma, in 3<jats:sup>rd<\/jats:sup> decade of life with characteristic cutaneous tumours was suggestive of a clinical diagnosis of MEN 1 syndrome. Recurrent, severe hypoglycaemia complicated with hypoglycaemic encephalopathy refractory to continuous, parenteral glucose supplementation and optimal pharmacotherapy complicated the clinical course. Insulinoma was localized with selective arterial calcium stimulation test. Distal pancreatectomy and four gland parathyroidectomy was performed leading to resolution of symptoms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Renal calculi or characteristic cutaneous lesions might be the only forewarning clinical manifestations of an undiagnosed MEN 1 syndrome impending a life-threatening presentation. Comprehensive management of MEN 1 syndrome requires multi-disciplinary approach with advanced imaging modalities, advanced surgical procedures and long-term follow up due to its heterogeneous presentation and the varying severity depending on the disease phenotype.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-022-00985-w","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T10:05:55Z","timestamp":1647425155000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Occult insulinoma with treatment refractory, severe hypoglycaemia in multiple endocrine neoplasia type 1 syndrome; difficulties faced during diagnosis, localization and management; a case report"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5065-5940","authenticated-orcid":false,"given":"Rasika","family":"Ranaweerage","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shehan","family":"Perera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harsha","family":"Sathischandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"key":"985_CR1","doi-asserted-by":"publisher","first-page":"5658","DOI":"10.1210\/jcem.86.12.8070","volume":"86","author":"ML Brandi","year":"2001","unstructured":"Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Consensus: guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658\u201371.","journal-title":"J Clin Endocrinol Metab"},{"key":"985_CR2","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1210\/jc.2012-1230","volume":"97","author":"RV Thakker","year":"2012","unstructured":"Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97:2990\u20133011.","journal-title":"J Clin Endocrinol Metab"},{"key":"985_CR3","doi-asserted-by":"publisher","first-page":"591501","DOI":"10.3389\/fendo.2020.591501","volume":"11","author":"C Mele","year":"2020","unstructured":"Mele C, Mencarelli M, Caputo M, Mai S, Pagano L, Aimaretti G, et al. Phenotypes associated with MEN1 syndrome: a focus on genotype-phenotype correlations. Front Endocrinol. 2020;11:591501.","journal-title":"Front Endocrinol."},{"key":"985_CR4","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1111\/jcmm.12552","volume":"19","author":"L Circelli","year":"2015","unstructured":"Circelli L, Ramundo V, Marotta V, Sciammarella C, Marciello F, Del Prete M, et al. Prognostic role of the CDNK1B V109G polymorphism in multiple endocrine neoplasia type 1. J Cell Mol Med. 2015;19:1735\u201341.","journal-title":"J Cell Mol Med"},{"key":"985_CR5","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1210\/jc.2008-2031","volume":"94","author":"KA Placzkowski","year":"2009","unstructured":"Placzkowski KA, Vella A, Thompson GB, Grant CS, Reading CC, Charboneau JW, et al. Secular trends in the presentation and management of functioning insulinoma at the mayo clinic, 1987\u20132007. J Clin Endocrinol Metab. 2009;94:1069\u201373.","journal-title":"J Clin Endocrinol Metab"},{"key":"985_CR6","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1053\/gast.1997.v112.pm9024313","volume":"112","author":"IM Modlin","year":"1997","unstructured":"Modlin IM, Tang LH. Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today). Gastroenterology. 1997;112:583\u201390.","journal-title":"Gastroenterology"},{"key":"985_CR7","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1007\/s00330-016-4216-7","volume":"26","author":"L Zhu","year":"2016","unstructured":"Zhu L, Xue H-D, Sun H, Wang X, He Y-L, Jin Z-Y, et al. Isoattenuating insulinomas at biphasic contrast-enhanced CT: frequency, clinicopathologic features and perfusion characteristics. Eur Radiol. 2016;26:3697\u2013705.","journal-title":"Eur Radiol"},{"key":"985_CR8","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1002\/jmri.25709","volume":"46","author":"L Zhu","year":"2017","unstructured":"Zhu L, Xue H, Sun Z, Li P, Qian T, Xing X, et al. Prospective comparison of biphasic contrast-enhanced CT, volume perfusion CT, and 3 Tesla MRI with diffusion-weighted imaging for insulinoma detection. J Magn Reson Imaging. 2017;46:1648\u201355.","journal-title":"J Magn Reson Imaging"},{"key":"985_CR9","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1200\/JCO.1998.16.7.2534","volume":"16","author":"H Orlefors","year":"1998","unstructured":"Orlefors H, Sundin A, Ahlstr\u00f6m H, Bjurling P, Bergstr\u00f6m M, Lilja A, et al. Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors. J Clin Oncol. 1998;16:2534\u201341.","journal-title":"J Clin Oncol"},{"key":"985_CR10","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1210\/jc.2006-1479","volume":"92","author":"S Kauhanen","year":"2007","unstructured":"Kauhanen S, Sepp\u00e4nen M, Minn H, Gullichsen R, Salonen A, Alanen K, et al. Fluorine-18-l-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or \u03b2-cell hyperplasia in adult patients. J Clin Endocrinol Metab. 2007;92:1237\u201344.","journal-title":"J Clin Endocrinol Metab"},{"key":"985_CR11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1749-6632.2002.tb04422.x","volume":"970","author":"B Eriksson","year":"2002","unstructured":"Eriksson B, Bergstr\u00d6M M, Sundin A, Juhlin C, \u00d6Rlefors H, \u00d6Berg K, et al. The role of PET in localization of neuroendocrine and adrenocortical tumors. Ann N Y Acad Sci. 2002;970:159\u201369.","journal-title":"Ann N Y Acad Sci"},{"key":"985_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s002590050197","volume":"25","author":"S Adams","year":"1998","unstructured":"Adams S, Baum R, Rink T, Schumm-Dr\u00e4ger P-M, Usadel K-H, H\u00f6r G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 1998;25:79\u201383.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"985_CR13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1148\/radiology.178.1.1984311","volume":"178","author":"JL Doppman","year":"1991","unstructured":"Doppman JL, Miller DL, Chang R, Shawker TH, Gorden P, Norton JA. Insulinomas: localization with selective intraarterial injection of calcium. Radiology. 1991;178:237\u201341.","journal-title":"Radiology"},{"key":"985_CR14","doi-asserted-by":"publisher","first-page":"4581094","DOI":"10.1155\/2016\/4581094","volume":"2016","author":"P Moreno-Moreno","year":"2016","unstructured":"Moreno-Moreno P, Alhambra-Exp\u00f3sito MR, Herrera-Mart\u00ednez AD, Palomares-Ortega R, Zurera-Tendero L, Espejo Herrero JJ, et al. Arterial calcium stimulation with hepatic venous sampling in the localization diagnosis of endogenous hyperinsulinism. Int J Endocrinol. 2016;2016:4581094.","journal-title":"Int J Endocrinol"},{"key":"985_CR15","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1097\/01.RVI.0000140638.55375.1E","volume":"15","author":"P Wiesli","year":"2004","unstructured":"Wiesli P, Br\u00e4ndle M, Schmid C, Kr\u00e4henb\u00fchl L, Furrer J, Keller U, et al. Selective arterial calcium stimulation and hepatic venous sampling in the evaluation of hyperinsulinemic hypoglycemia: potential and limitations. J Vasc Interv Radiol. 2004;15:1251\u20136.","journal-title":"J Vasc Interv Radiol"},{"key":"985_CR16","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1148\/radiology.206.3.9494488","volume":"206","author":"PL Pereira","year":"1998","unstructured":"Pereira PL, Roche AJ, Maier GW, Huppert PE, Dammann F, Farnsworth CT, et al. Insulinoma and islet cell hyperplasia: value of the calcium intraarterial stimulation test when findings of other preoperative studies are negative. Radiology. 1998;206:703\u20139.","journal-title":"Radiology"},{"key":"985_CR17","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1245\/s10434-007-9398-4","volume":"14","author":"L-M Tseng","year":"2007","unstructured":"Tseng L-M, Chen J-Y, Won JG-S, Tseng H-S, Yang A-H, Wang S-E, et al. The role of intra-arterial calcium stimulation test with hepatic venous sampling (IACS) in the management of occult insulinomas. Ann Surg Oncol. 2007;14:2121\u20137.","journal-title":"Ann Surg Oncol"},{"key":"985_CR18","first-page":"884","volume":"47","author":"A Chatziioannou","year":"2000","unstructured":"Chatziioannou A, Mourikis D, Konstandinidis P, Kehagias D, Vlachos L. Preoperative localization of pancreatic insulinoma by selective intraarterial calcium injection and hepatic venous sampling. Hepatogastroenterology. 2000;47:884\u20136.","journal-title":"Hepatogastroenterology"},{"key":"985_CR19","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1067\/msy.2000.109729","volume":"128","author":"CY Lo","year":"2000","unstructured":"Lo CY, Chan FL, Tam SCF, Cheng PW, Fan ST, Lam KSL. Value of intra-arterial calcium stimulated venous sampling for regionalization of pancreatic insulinomas. Surgery. 2000;128:903\u20139.","journal-title":"Surgery"},{"key":"985_CR20","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S0025-6196(12)62083-7","volume":"66","author":"MM McMahon","year":"1991","unstructured":"Service FJ, McMahon MM, O\u2019Brien PC, Ballard DJ. Functioning insulinoma\u2014incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc. 1991;66:711\u20139.","journal-title":"Mayo Clin Proc"},{"key":"985_CR21","first-page":"998","volume":"110","author":"MJ Demeure","year":"1991","unstructured":"Demeure MJ, Klonoff DC, Karam JH, Duh QY, Clark OH. Insulinomas associated with multiple endocrine neoplasia type I: the need for a different surgical approach. Am J Surg. 1991;110:998\u20131004.","journal-title":"Am J Surg"},{"key":"985_CR22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1001\/archsurg.2011.1843","volume":"147","author":"S Crippa","year":"2012","unstructured":"Crippa S, Zerbi A, Boninsegna LC,V, Partelli S, Balzano G, Pederzoli P, et al. Surgical\u00a0 management of insulinomas: short-and long-term outcomes after enucleations and pancreatic resections. Arch Surg. 2012;147:261\u20136.","journal-title":"Arch Surg."},{"key":"985_CR23","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s00423-011-0828-1","volume":"396","author":"CL Lopez","year":"2011","unstructured":"Lopez CL, Waldmann J, Fendrich V, Langer P, Kann PH, Bartsch DK. Long-term results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN1. Langenbeck\u2019s Arch Surg. 2011;396:1187\u201396.","journal-title":"Langenbeck's Arch Surg"},{"key":"985_CR24","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1159\/000357779","volume":"98","author":"DK Bartsch","year":"2013","unstructured":"Bartsch DK, Albers M, Knoop R, Kann PH, Fendrich V, Waldmann J. Enucleation and limited pancreatic resection provide long-term cure for insulinoma in multiple endocrine neoplasia type 1. Neuroendocrinology. 2013;98:290\u20138.","journal-title":"Neuroendocrinology"},{"key":"985_CR25","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00270-007-9185-4","volume":"31","author":"G Rott","year":"2007","unstructured":"Rott G, Biggemann M, Pfohl M. Embolization of an insulinoma of the pancreas with trisacryl gelatin microspheres as definitive treatment. Cardiovasc Interv Radiol. 2007;31:659\u201362.","journal-title":"Cardiovasc Interv Radiol"},{"key":"985_CR26","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.1982.03330110049026","volume":"248","author":"TJ Moore","year":"1982","unstructured":"Moore TJ, Peterson LM, Harrington DP, Smith RJ. Successful arterial embolization of an insulinoma. JAMA. 1982;248:1353\u20135.","journal-title":"JAMA"},{"key":"985_CR27","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00270-008-9499-x","volume":"32","author":"M Peppa","year":"2009","unstructured":"Peppa M, Brountzos\u00a0E, Economopoulos N, Boutati E, Pikounis V, Patapis P, et al. Embolization as an alternative treatment of insulinoma in a patient with multiple endocrine neoplasia type 1 syndrome. Cardiovasc Interv Radiol. 2009;32:807\u201311.","journal-title":"Cardiovasc Interv Radiol"},{"key":"985_CR28","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1001\/archderm.1997.03890430067009","volume":"133","author":"TN Darling","year":"1997","unstructured":"Darling TN, Skarulis MC, Steinberg SM, Marx S J, Spiegel AM, Turner M. Multiple\u00a0facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch Dermatol. 1997;133:853\u20137.","journal-title":"Arch Dermatol."},{"key":"985_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4038\/sjdem.v10i1.7406","volume":"10","author":"P Wijewickrama","year":"2020","unstructured":"Wijewickrama P, Somasundaram N, Gunasekera C. What lies beneath - Skin as a window to an underlying complex disorder. Sri Lanka J Diabetes Endocrinol Metab. 2020;10:38.","journal-title":"Sri Lanka J Diabetes Endocrinol Metab"},{"key":"985_CR30","doi-asserted-by":"publisher","first-page":"5328","DOI":"10.1210\/jc.2004-0218","volume":"89","author":"B Asgharian","year":"2004","unstructured":"Asgharian B, Turner ML, Gibril F, Entsuah LK, Serrano J, Jensen RT. Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas: prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1. J Clin Endocrinol Metab. 2004;89:5328\u201336.","journal-title":"J Clin Endocrinol Metab"},{"key":"985_CR31","first-page":"223","volume-title":"Endocrine tumors of the pancreas","author":"M Mignon","year":"1994","unstructured":"Mignon M, Jais PH, Cadiot G, Yedder DB, Vatier J. Clinical features and advances in biological diagnostic criteria for Zollinger-Ellison syndrome. In: Mignon M, Jensen RT, editors. Endocrine tumors of the pancreas. Basel: Karger Publishers; 1994. p. 223\u201339."},{"key":"985_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/01.md.0000112297.72510.32","volume":"83","author":"F Gibril","year":"2004","unstructured":"Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Medicine. 2004;83:43\u201383.","journal-title":"Medicine"},{"key":"985_CR33","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/S0016-5085(99)70124-1","volume":"116","author":"G Cadiot","year":"1999","unstructured":"Cadiot G, Vuagnat A, Doukhan I, Murat A, Bonnaud G, Delemer B, et al. Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Gastroenterology. 1999;116:286\u201393.","journal-title":"Gastroenterology"},{"key":"985_CR34","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1111\/j.1464-410X.2005.05731.x","volume":"96","author":"C Christopoulos","year":"2005","unstructured":"Christopoulos C, Antoniou N, Thempeyioti A, Calender A, Economopoulos P. Familial multiple endocrine neoplasia type I: the urologist is first on the scene. BJU Int. 2005;96:884\u20137.","journal-title":"BJU Int"},{"key":"985_CR35","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1359\/jbmr.090304","volume":"24","author":"C Eller-Vainicher","year":"2009","unstructured":"Eller-Vainicher C, Chiodini I, Battista C, Viti R, Mascia ML, Massironi S, et al. Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity. J Bone Miner Res. 2009;24:1404\u201310.","journal-title":"J Bone Miner Res"},{"key":"985_CR36","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/0002-9343(79)91062-3","volume":"66","author":"CBHW Lamers","year":"1979","unstructured":"Lamers CBHW, Froeling PGAM. Clinical significance of hyperparathyroidism in familial multiple endocrine adenomatosis type I (MEA I). Am J Med. 1979;66:422\u20134.","journal-title":"Am J Med"},{"key":"985_CR37","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1002\/jbmr.125","volume":"25","author":"DM Louren\u00e7o","year":"2010","unstructured":"Louren\u00e7o DM, Coutinho FL, Toledo RA, Montenegro FLM, Correia-Deur JEM, Toledo SPA. Early-onset, progressive, frequent, extensive, and severe bone mineral and renal complications in multiple endocrine neoplasia type 1-associated primary hyperparathyroidism. J Bone Miner Res. 2010;25:2382\u201391.","journal-title":"J Bone Miner Res"},{"key":"985_CR38","doi-asserted-by":"publisher","first-page":"F1000 Faculty R","DOI":"10.12688\/f1000research.7230.1","volume":"6","author":"A Falchetti","year":"2017","unstructured":"Falchetti A. Genetics of multiple endocrine neoplasia type 1 syndrome: what\u2019s new and what\u2019s old. F1000Res. 2017;6:F1000 Faculty Rev-73.","journal-title":"F1000Res"},{"key":"985_CR39","first-page":"2617","volume":"83","author":"RV Thakker","year":"1998","unstructured":"Thakker RV. Multiple endocrine neoplasia\u2013syndromes of the twentieth century. J Clin Endocrinol Metab. 1998;83:2617\u201320.","journal-title":"J Clin Endocrinol Metab"},{"key":"985_CR40","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s002680010237","volume":"24","author":"PG Dean","year":"2000","unstructured":"Dean PG, van Heerden JA, Farley DR, Thompson GB, Grant CS, Harmsen WS, et al. Are patients with multiple endocrine neoplasia type i prone to premature death? World J Surg. 2000;24:1437\u201341.","journal-title":"World J Surg"},{"key":"985_CR41","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1530\/eje.0.1490577","volume":"149","author":"EA Geerdink","year":"2003","unstructured":"Geerdink EA, Van der Luijt RB, Lips CJ. Do patients with multiple endocrine neoplasia syndrome type 1 benefit from periodical screening? Eur J Endocrinol. 2003;149:577\u201382.","journal-title":"Eur J Endocrinol"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-00985-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-022-00985-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-00985-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T17:03:37Z","timestamp":1666717417000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-022-00985-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["985"],"URL":"https:\/\/doi.org\/10.1186\/s12902-022-00985-w","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,16]]},"assertion":[{"value":"16 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed written consent was taken from the patient to publish the details relevant to the disease for this scientific publication. The copy of consent form is available for review if deemed necessary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they do not have any competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}